Category - News

Developments

Satisfied TULSA prostate cancer procedure patient discloses 5.2% stake in Profound Medical

In a 13G filed with the SEC today, accomplished businessman and founder of namesake transportation company Daseke (NADAQ:DSKE), Don Daseke, disclosed he has taken a 5.2% ownership stake in Profound Medical (NASDAQ:PROF)...

January 12, 2024

Developments

Sigyn outlines 2023 achievements, 2024 outlook

In a letter to shareholders to Sigyn Therapeutics’ (OTCQB:SIGY) shareholders, Jim Joyce, chairman and CEO, said as a small organization operating in a world with short-term expectations, the company has “not wavered...

January 8, 2024

Markets

Avenue Therapeutics Reaches Final Agreement with FDA for the Phase 3 Safety Study for IV Tramadol

Fortress Biotech (NASDAQ:FBIO) partner company, Avenue Therapeutics (NASDAQ:ATXI) announced that it reached a final agreement with the FDA on the Phase 3 safety study protocol and statistical analysis approach...

January 4, 2024

Developments

IntelGenx enters VetaFilm development license agreements under new animal health partnership

IntelGenx (TSX:IGX; OTCQB:IGXT) entered into development and license agreements with a wholly owned subsidiary of Covenant Animal Health Partners, who will fund the development and manufacturing of a VetaFilm-based drug...

December 18, 2023

Executive Moves

Sigyn Therapeutics names Jerry DeCiccio as CFO

Sigyn Therapeutics (OTCQB:SIGY) appointed Jerry DeCiccio as CFO, succeeding Jeremy Farrell, who was appointed CFO in March of 2022. Mr. DeCiccio has more than 40 years of financial industry experience, previously...

December 12, 2023

Developments Markets

Hepion reports restructuring and resignations; Brookline downgrades to hold and suspends target

Hepion Pharmaceuticals (NASDAQ:HEPA) announced a restructuring that, among other things, will suspend the enrollment of new patients in the Phase 2b ‘ASCEND-NASH’ clinical trial of its lead drug candidate, rencofilstat...

December 7, 2023

Developments

Anixa reports positive new data from Phase 1 breast cancer vaccine trial

Anixa Biosciences (NASDAQ:ANIX) and its partner, Cleveland Clinic, presented positive new results from the Phase 1 clinical trial of Anixa’s breast cancer vaccine at the 2023 San Antonio Breast Cancer Symposium (SABCS)...

December 7, 2023

Markets

Evercore starts Gracell Biotech at OP

Evercore ISI initiated coverage of Gracell Biotechnologies (NASDAQ:GRCL) with an “outperform” rating and no price target. The stock was quoted at $5.43 midday on Nov. 27. Gracell is developing a unique CAR-T construct...

November 27, 2023

Developments

Anixa reports European patent for ovarian cancer vaccine technology

Anixa Biosciences (NASDAQ:ANIX) reported that its partner, Cleveland Clinic, received an intention-to-grant notice from the European Patent Office (EPO) for the patent application covering the company’s ovarian cancer...

November 27, 2023

Developments

SHINE Technologies, Nucleus RadioPharma in long-term supply pact

SHINE Technologies and Nucleus RadioPharma entered a multi-year supply agreement for lutetium-177, a radiopharmaceutical that is used for targeted cancer treatment. Nucleus, a contract development and manufacturing...

November 17, 2023

Category - News

Satisfied TULSA prostate cancer procedure patient discloses 5.2% stake in Profound Medical

Sigyn outlines 2023 achievements, 2024 outlook

Avenue Therapeutics Reaches Final Agreement with FDA for the Phase 3 Safety Study for IV Tramadol

IntelGenx enters VetaFilm development license agreements under new animal health partnership

Sigyn Therapeutics names Jerry DeCiccio as CFO

Hepion reports restructuring and resignations; Brookline downgrades to hold and suspends target

Anixa reports positive new data from Phase 1 breast cancer vaccine trial

Evercore starts Gracell Biotech at OP

Anixa reports European patent for ovarian cancer vaccine technology

SHINE Technologies, Nucleus RadioPharma in long-term supply pact

General

More